BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, Himanen SL, Hublin C, Julkunen I, Olsén P, Saarenpää-Heikkilä O, Kilpi T. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012;7:e33536. [PMID: 22470453 DOI: 10.1371/journal.pone.0033536] [Cited by in Crossref: 351] [Cited by in F6Publishing: 295] [Article Influence: 35.1] [Reference Citation Analysis]
Number Citing Articles
1 Keitel WA, Piedra PA. Influenza A(H5N1) vaccines: are we better prepared for the next pandemic? J Infect Dis 2014;209:1-3. [PMID: 24158956 DOI: 10.1093/infdis/jit573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opinion on Investigational Drugs 2018;27:389-406. [DOI: 10.1080/13543784.2018.1459561] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
3 Kotloff KL, Halasa NB, Harrison CJ, Englund JA, Walter EB, King JC, Creech CB, Healy SA, Dolor RJ, Stephens I, Edwards KM, Noah DL, Hill H, Wolff M. Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children. Pediatr Infect Dis J 2014;33:865-71. [PMID: 25222307 DOI: 10.1097/INF.0000000000000329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Partinen M, Kronholm E. Epidemiology: Principles and Application in Sleep Medicine. In: Chokroverty S, editor. Sleep Disorders Medicine. New York: Springer; 2017. pp. 485-521. [DOI: 10.1007/978-1-4939-6578-6_28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Oberle D, Pavel J, Mayer G, Geisler P, Keller-Stanislawski B; German Narcolepsy Study Group. Retrospective multicenter matched case-control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany. Sleep Med 2017;34:71-83. [PMID: 28522102 DOI: 10.1016/j.sleep.2017.02.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
6 Giannoccaro MP, Sallemi G, Liguori R, Plazzi G, Pizza F. Immunotherapy in Narcolepsy. Curr Treat Options Neurol 2020;22:2. [PMID: 31997035 DOI: 10.1007/s11940-020-0609-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59(®) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013;12:13-30. [PMID: 23256736 DOI: 10.1586/erv.12.140] [Cited by in Crossref: 162] [Cited by in F6Publishing: 152] [Article Influence: 18.0] [Reference Citation Analysis]
8 Cauchi M, Ball H, Ben-Shlomo Y, Robertson N. Interpretation of vaccine associated neurological adverse events: a methodological and historical review. J Neurol 2021. [PMID: 34398270 DOI: 10.1007/s00415-021-10747-8] [Reference Citation Analysis]
9 Ahout I, Ferwerda G, de Groot R. Influenza vaccination in kids, are you kidding me? Journal of Infection 2014;68:S100-7. [DOI: 10.1016/j.jinf.2013.09.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 González de Dios J, Rodrigo Gonzalo de Liria C, Piedra PA, Corretger Rauet JM, Moreno-Pérez D. [Universal immunisation against influenza in paediatrics, yes or no?]. An Pediatr (Barc) 2013;79:261.e1-261.e11. [PMID: 23623850 DOI: 10.1016/j.anpedi.2013.03.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Jalilian B, Christiansen SH, Einarsson HB, Pirozyan MR, Petersen E, Vorup-Jensen T. Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities? Mol Cell Ther 2013;1:2. [PMID: 26056568 DOI: 10.1186/2052-8426-1-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
12 Principi N, Senatore L, Esposito S. Protection of young children from influenza through universal vaccination. Hum Vaccin Immunother 2015;11:2350-8. [PMID: 26090704 DOI: 10.1080/21645515.2015.1055428] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
13 Petrovsky N. Vaccine adjuvant safety: the elephant in the room. Expert Rev Vaccines 2013;12:715-7. [PMID: 23885815 DOI: 10.1586/14760584.2013.811198] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
14 Jacob L, Dauvilliers Y. La narcolepsie avec cataplexie : une maladie auto-immune ? Med Sci (Paris) 2014;30:1136-43. [DOI: 10.1051/medsci/20143012017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
15 Agmon-levin N, Arango M, Kivity S, Katzav A, Gilburd B, Blank M, Tomer N, Volkov A, Barshack I, Chapman J, Shoenfeld Y. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. Journal of Autoimmunity 2014;54:21-32. [DOI: 10.1016/j.jaut.2014.06.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
16 Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, Cohet C, Innis BL, Fries LF. Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials. Hum Vaccin Immunother 2014;10:2942-57. [PMID: 25483467 DOI: 10.4161/21645515.2014.972149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
17 Naruse T, Fukuda T, Tanabe T, Ichikawa M, Oda Y, Tochihara S, Kimachi K, Kino Y, Ueda K. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03. Vaccine 2015;33:6078-84. [PMID: 26409141 DOI: 10.1016/j.vaccine.2015.09.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
18 Salmon DA, Lambert PH, Nohynek HM, Gee J, Parashar UD, Tate JE, Wilder-Smith A, Hartigan-Go KY, Smith PG, Zuber PLF. Novel vaccine safety issues and areas that would benefit from further research. BMJ Glob Health 2021;6:e003814. [PMID: 34011502 DOI: 10.1136/bmjgh-2020-003814] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Tyree SM, Borniger JC, de Lecea L. Hypocretin as a Hub for Arousal and Motivation. Front Neurol 2018;9:413. [PMID: 29928253 DOI: 10.3389/fneur.2018.00413] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
20 Sturkenboom MC. The narcolepsy-pandemic influenza story: Can the truth ever be unraveled? Vaccine 2015;33:B6-B13. [DOI: 10.1016/j.vaccine.2015.03.026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
21 Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res 2013;178:78-98. [PMID: 23726847 DOI: 10.1016/j.virusres.2013.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 7.6] [Reference Citation Analysis]
22 Kim WJ, Lee SD, Lee E, Namkoong K, Choe KW, Song JY, Cheong HJ, Jeong HW, Heo JY. Incidence of narcolepsy before and after MF59-adjuvanted influenza A(H1N1)pdm09 vaccination in South Korean soldiers. Vaccine 2015;33:4868-72. [PMID: 26238720 DOI: 10.1016/j.vaccine.2015.07.055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
23 Fugger L, Steinman L. A scientific sequel to Stieg Larsson: relationship between Pandemrix--pandemic influenza vaccine--and the subsequent development of narcolepsy. J Intern Med 2014;275:195-7. [PMID: 24286291 DOI: 10.1111/joim.12158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Blackwell JE, Alammar HA, Weighall AR, Kellar I, Nash HM. A systematic review of cognitive function and psychosocial well-being in school-age children with narcolepsy. Sleep Medicine Reviews 2017;34:82-93. [DOI: 10.1016/j.smrv.2016.07.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
25 Palache A, Oriol-Mathieu V, Abelin A, Music T; Influenza Vaccine Supply task force (IFPMA IVS). Seasonal influenza vaccine dose distribution in 157 countries (2004-2011). Vaccine 2014;32:6369-76. [PMID: 25442403 DOI: 10.1016/j.vaccine.2014.07.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
26 Esposito S, Prada E, Mastrolia MV, Tarantino G, Codecà C, Rigante D. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): clues and pitfalls in the pediatric background. Immunol Res 2014;60:366-75. [PMID: 25395340 DOI: 10.1007/s12026-014-8586-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
27 Feng H, Yamashita M, Wu L, Jose da Silva Lopes T, Watanabe T, Kawaoka Y. Food Additives as Novel Influenza Vaccine Adjuvants. Vaccines (Basel) 2019;7:E127. [PMID: 31554190 DOI: 10.3390/vaccines7040127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Ollila HM, Ravel JM, Han F, Faraco J, Lin L, Zheng X, Plazzi G, Dauvilliers Y, Pizza F, Hong SC, Jennum P, Knudsen S, Kornum BR, Dong XS, Yan H, Hong H, Coquillard C, Mahlios J, Jolanki O, Einen M, Arnulf I, Högl B, Frauscher B, Crowe C, Partinen M, Huang YS, Bourgin P, Vaarala O, Désautels A, Montplaisir J, Mack SJ, Mindrinos M, Fernandez-Vina M, Mignot E. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet 2015;96:136-46. [PMID: 25574827 DOI: 10.1016/j.ajhg.2014.12.010] [Cited by in Crossref: 98] [Cited by in F6Publishing: 82] [Article Influence: 14.0] [Reference Citation Analysis]
29 Jacob L, Leib R, Ollila HM, Bonvalet M, Adams CM, Mignot E. Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun 2015;47:44-57. [PMID: 25452148 DOI: 10.1016/j.bbi.2014.11.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
30 Skufca J, Ollgren J, Ruokokoski E, Lyytikäinen O, Nohynek H. Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002-2012. Papillomavirus Res 2017;3:91-6. [PMID: 28720463 DOI: 10.1016/j.pvr.2017.03.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
31 Neuzil KM, Tsvetnitsky V, Nyari LJ, Bright RA, Boslego JW; PATH's Influenza Vaccine Project team. PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries. Expert Rev Vaccines 2012;11:939-47. [PMID: 23002975 DOI: 10.1586/erv.12.76] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Han F, Lin L, Li J, Dong XS, Mignot E. Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Ann Neurol 2013;73:560. [PMID: 23225098 DOI: 10.1002/ana.23799] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
33 Baum U, Leino T, Gissler M, Kilpi T, Jokinen J. Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified by trimester of vaccination. Vaccine 2015;33:4850-7. [PMID: 26238723 DOI: 10.1016/j.vaccine.2015.07.061] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
34 Salmon DA, Halsey NA. Editorial Commentary: Guillain-Barre Syndrome and Vaccinations. Clinical Infectious Diseases 2013;57:205-7. [DOI: 10.1093/cid/cit218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Kårhus LL, Gunnes N, Størdal K, Bakken IJ, Tapia G, Stene LC, Håberg SE, Mårild K. Influenza and risk of later celiac disease: a cohort study of 2.6 million people. Scandinavian Journal of Gastroenterology 2018;53:15-23. [DOI: 10.1080/00365521.2017.1362464] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
36 Lee Y, Lee YS, Cho SY, Kwon HJ. Perspective of Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers. Adv Protein Chem Struct Biol 2015;99:75-97. [PMID: 26067817 DOI: 10.1016/bs.apcsb.2015.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 Poli F, Overeem S, Lammers GJ, Plazzi G, Lecendreux M, Bassetti CL, Dauvilliers Y, Keene D, Khatami R, Li Y, Mayer G, Nohynek H, Pahud B, Paiva T, Partinen M, Scammell TE, Shimabukuro T, Sturkenboom M, van Dinther K, Wiznitzer M, Bonhoeffer J. Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. Vaccine 2013;31:994-1007. [DOI: 10.1016/j.vaccine.2012.12.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
38 Bivona JJ 3rd, Patel S, Vajdy M. Induction of cellular and molecular Immunomodulatory pathways by vitamin E and vitamin C. Expert Opin Biol Ther 2017;17:1539-51. [PMID: 28905653 DOI: 10.1080/14712598.2017.1375096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
39 Dye TJ, Gurbani N, Simakajornboon N. Epidemiology and Pathophysiology of Childhood Narcolepsy. Paediatr Respir Rev 2018;25:14-8. [PMID: 28108192 DOI: 10.1016/j.prrv.2016.12.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
40 Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1-16. [PMID: 24238833 DOI: 10.1016/j.jaut.2013.10.004] [Cited by in Crossref: 141] [Cited by in F6Publishing: 118] [Article Influence: 15.7] [Reference Citation Analysis]
41 Melén K, Jalkanen P, Kukkonen JP, Partinen M, Nohynek H, Vuorela A, Vaarala O, Freitag TL, Meri S, Julkunen I. No evidence of autoimmunity to human OX1 or OX2 orexin receptors in Pandemrix-vaccinated narcoleptic children. J Transl Autoimmun 2020;3:100055. [PMID: 32743535 DOI: 10.1016/j.jtauto.2020.100055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Nolan T, Izurieta P, Lee BW, Chan PC, Marshall H, Booy R, Drame M, Vaughn DW. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age. J Infect Dis 2014;210:1800-10. [PMID: 24973461 DOI: 10.1093/infdis/jiu359] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
43 Zhang X, Penzel T, Han F. Increased incidence of narcolepsy following the 2009 H1N1 pandemic. Somnologie 2013;17:90-3. [DOI: 10.1007/s11818-013-0619-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
44 Klemm C, Das E, Hartmann T. Changed priorities ahead: Journalists' shifting role perceptions when covering public health crises. Journalism (Lond) 2019;20:1223-41. [PMID: 34253953 DOI: 10.1177/1464884917692820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
45 Boraschi D, Aguado MT, Dutel C, Goronzy J, Louis J, Grubeck-Loebenstein B, Rappuoli R, Del Giudice G. The gracefully aging immune system. Sci Transl Med 2013;5:185ps8. [PMID: 23677590 DOI: 10.1126/scitranslmed.3005624] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 10.0] [Reference Citation Analysis]
46 Stowe J, Andrews N, Gringras P, Quinnell T, Zaiwalla Z, Shneerson J, Miller E. Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study. PLoS Med 2020;17:e1003225. [PMID: 32926731 DOI: 10.1371/journal.pmed.1003225] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Sasaki E, Momose H, Hiradate Y, Mizukami T, Hamaguchi I. Establishment of a novel safety assessment method for vaccine adjuvant development. Vaccine 2018;36:7112-8. [PMID: 30318166 DOI: 10.1016/j.vaccine.2018.10.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
48 Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanta M; Influenza Vaccine Supply task force (IFPMA IVS). Seasonal influenza vaccine dose distribution in 195 countries (2004-2013): Little progress in estimated global vaccination coverage. Vaccine 2015;33:5598-605. [PMID: 26368399 DOI: 10.1016/j.vaccine.2015.08.082] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 9.4] [Reference Citation Analysis]
49 Li Z, Zhao Y, Li Y, Chen X. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines (Basel) 2021;9:75. [PMID: 33494477 DOI: 10.3390/vaccines9020075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine 2016;34:714-22. [PMID: 26740250 DOI: 10.1016/j.vaccine.2015.12.024] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
51 Heikkinen T, Tsolia M, Finn A. Vaccination of Healthy Children Against Seasonal Influenza: A European Perspective. Pediatric Infectious Disease Journal 2013;32:881-8. [DOI: 10.1097/inf.0b013e3182918168] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
52 Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, Godeaux O, Izurieta P, Vaughn DW. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial. J Infect Dis 2015;211:801-10. [PMID: 25293368 DOI: 10.1093/infdis/jiu548] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
53 Burgess CR, Scammell TE. Narcolepsy: neural mechanisms of sleepiness and cataplexy. J Neurosci 2012;32:12305-11. [PMID: 22956821 DOI: 10.1523/JNEUROSCI.2630-12.2012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
54 Derrough T, Olsson K, Gianfredi V, Simondon F, Heijbel H, Danielsson N, Kramarz P, Pastore-Celentano L. Immunisation Information Systems - useful tools for monitoring vaccination programmes in EU/EEA countries, 2016. Euro Surveill 2017;22:30519. [PMID: 28488999 DOI: 10.2807/1560-7917.ES.2017.22.17.30519] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
55 Edwards K, Lambert PH, Black S. Narcolepsy and Pandemic Influenza Vaccination: What We Need to Know to be Ready for the Next Pandemic. Pediatr Infect Dis J 2019;38:873-6. [PMID: 31306400 DOI: 10.1097/INF.0000000000002398] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
56 Chen YH, Huang YS, Chien WH, Chen CH. Association analysis of the major histocompatibility complex, class II, DQ β1 gene, HLA-DQB1, with narcolepsy in Han Chinese patients from Taiwan. Sleep Med 2013;14:1393-7. [PMID: 24157097 DOI: 10.1016/j.sleep.2013.06.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
57 Ferguson D, Wrigley S, Purcell E, Keane S, McGinn B, O'Malley S, Lynch B, Crowe C. Single center analysis of patients with H1N1 vaccine-related narcolepsy and sporadic narcolepsy presenting over the same time period. J Clin Sleep Med 2021;17:885-95. [PMID: 33289477 DOI: 10.5664/jcsm.9052] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, d'Ortho MP, Launois S, Lignot S, Bourgin P, Nogues B, Rey M, Bayard S, Scholz S, Lavault S, Tubert-Bitter P, Saussier C, Pariente A; Narcoflu-VF study group. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013;136:2486-96. [PMID: 23884811 DOI: 10.1093/brain/awt187] [Cited by in Crossref: 163] [Cited by in F6Publishing: 126] [Article Influence: 18.1] [Reference Citation Analysis]
59 Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol 2013;23:767-73. [PMID: 23725858 DOI: 10.1016/j.conb.2013.04.013] [Cited by in Crossref: 110] [Cited by in F6Publishing: 84] [Article Influence: 12.2] [Reference Citation Analysis]
60 Verstraeten T, Cohet C, Dos Santos G, Ferreira GL, Bollaerts K, Bauchau V, Shinde V. Pandemrix™ and narcolepsy: A critical appraisal of the observational studies. Hum Vaccin Immunother 2016;12:187-93. [PMID: 26379011 DOI: 10.1080/21645515.2015.1068486] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
61 Saarela O, Hanley JA. Case-base methods for studying vaccination safety: Case-base methods for studying vaccination safety. Biom 2015;71:42-52. [DOI: 10.1111/biom.12222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
62 Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. Sleep Med Rev 2018;38:177-86. [PMID: 28847694 DOI: 10.1016/j.smrv.2017.06.006] [Cited by in Crossref: 83] [Cited by in F6Publishing: 66] [Article Influence: 16.6] [Reference Citation Analysis]
63 Lamb F, Ploner A, Fink K, Maeurer M, Bergman P, Piehl F, Weibel D, Sparén P, Dahlström LA. No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination. PLoS One 2016;11:e0154296. [PMID: 27120092 DOI: 10.1371/journal.pone.0154296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 Syrjänen RK, Jokinen J, Ziegler T, Sundman J, Lahdenkari M, Julkunen I, Kilpi TM. Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland. PLoS One 2014;9:e108538. [PMID: 25265186 DOI: 10.1371/journal.pone.0108538] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
65 Oberle D, Drechsel-Bäuerle U, Schmidtmann I, Mayer G, Keller-Stanislawski B. Incidence of Narcolepsy in Germany. Sleep 2015;38:1619-28. [PMID: 25902804 DOI: 10.5665/sleep.5060] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
66 Khazeni N, Hutton DW, Collins CI, Garber AM, Owens DK. Health and economic benefits of early vaccination and nonpharmaceutical interventions for a human influenza A (H7N9) pandemic: a modeling study. Ann Intern Med 2014;160:684-94. [PMID: 24842415 DOI: 10.7326/M13-2071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
67 Postiglione E, Antelmi E, Pizza F, Lecendreux M, Dauvilliers Y, Plazzi G. The clinical spectrum of childhood narcolepsy. Sleep Medicine Reviews 2018;38:70-85. [DOI: 10.1016/j.smrv.2017.04.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
68 Ludvigsson JF, Zugna D, Cnattingius S, Richiardi L, Ekbom A, Örtqvist Å, Persson I, Stephansson O. Influenza H1N1 vaccination and adverse pregnancy outcome. Eur J Epidemiol 2013;28:579-88. [DOI: 10.1007/s10654-013-9813-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
69 Golchin M, Moghadaszadeh M, Tavakkoli H, Ghanbarpour R, Dastmalchi S. Recombinant M2e-HA2 fusion protein induced immunity responses against intranasally administered H9N2 influenza virus. Microb Pathog 2018;115:183-8. [PMID: 29273512 DOI: 10.1016/j.micpath.2017.12.050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
70 Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, Petrovsky N. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. Vaccine 2012;30:5407-16. [PMID: 22717330 DOI: 10.1016/j.vaccine.2012.06.009] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 8.2] [Reference Citation Analysis]
71 Seo YB, Moon SJ, Jeon CH, Song JY, Sung YK, Jeong SJ, Kwon KT, Kim ES, Kim JH, Kim HA, Park DJ, Park SH, Park JK, Ahn JK, Oh JS, Yun JW, Lee JH, Lee HY, Choi MJ, Choi WS, Choi YH, Choi JH, Heo JY, Cheong HJ, Lee SS. The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease. Infect Chemother 2020;52:252-80. [PMID: 32618150 DOI: 10.3947/ic.2020.52.2.252] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
72 Salo-Tuominen K, Teros-Jaakkola T, Toivonen L, Ollila H, Rautava P, Aromaa M, Lahti E, Junttila N, Peltola V. Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children. Vaccine 2022:S0264-410X(22)00582-5. [PMID: 35595660 DOI: 10.1016/j.vaccine.2022.05.012] [Reference Citation Analysis]
73 Cao W, Liepkalns JS, Kamal RP, Reber AJ, Kim JH, Hofstetter AR, Amoah S, Stevens J, Ranjan P, Gangappa S, York IA, Sambhara S. RIG-I ligand enhances the immunogenicity of recombinant H7HA protein. Cell Immunol 2016;304-305:55-8. [PMID: 27106062 DOI: 10.1016/j.cellimm.2016.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
74 Kennedy RB, Ovsyannikova IG, Poland GA. Update on Influenza Vaccines: Needs and Progress. J Allergy Clin Immunol Pract 2021;9:3599-603. [PMID: 34416408 DOI: 10.1016/j.jaip.2021.08.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Pellegrino P, Clementi E, Radice S. On vaccine's adjuvants and autoimmunity: Current evidence and future perspectives. Autoimmunity Reviews 2015;14:880-8. [DOI: 10.1016/j.autrev.2015.05.014] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 8.6] [Reference Citation Analysis]
76 Bakhtadze S, Lim M, Craiu D, Cazacu C. Vaccination in acute immune-mediated/inflammatory disorders of the central nervous system. Eur J Paediatr Neurol 2021;34:118-22. [PMID: 34487956 DOI: 10.1016/j.ejpn.2021.07.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Pérez-Carbonell L, Leschziner G. Clinical update on central hypersomnias. J Thorac Dis 2018;10:S112-23. [PMID: 29445535 DOI: 10.21037/jtd.2017.10.161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
78 Bresee JS, Fry AM, Sambhara S, Cox NJ. Inactivated Influenza Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 456-488.e21. [DOI: 10.1016/b978-0-323-35761-6.00031-6] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
79 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
80 Juvet LK, Robertson AH, Laake I, Mjaaland S, Trogstad L. Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews. Front Immunol 2021;12:740048. [PMID: 34777351 DOI: 10.3389/fimmu.2021.740048] [Reference Citation Analysis]
81 Löffler P. Review: Vaccine Myth-Buster - Cleaning Up With Prejudices and Dangerous Misinformation. Front Immunol 2021;12:663280. [PMID: 34177902 DOI: 10.3389/fimmu.2021.663280] [Reference Citation Analysis]
82 Black SW, Kilduff TS. H1N1 infection of sleep/wake regions results in narcolepsy-like symptoms. Proc Natl Acad Sci USA 2016;113:476-7. [DOI: 10.1073/pnas.1524150113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Lee BY, Shah M. Prevention of influenza in healthy children. Expert Rev Anti Infect Ther 2012;10:1139-52. [PMID: 23199400 DOI: 10.1586/eri.12.106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
84 Wilkins AL, Kazmin D, Napolitani G, Clutterbuck EA, Pulendran B, Siegrist CA, Pollard AJ. AS03- and MF59-Adjuvanted Influenza Vaccines in Children. Front Immunol 2017;8:1760. [PMID: 29326687 DOI: 10.3389/fimmu.2017.01760] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 11.4] [Reference Citation Analysis]
85 Duffy J, Weintraub E, Vellozzi C, DeStefano F; Vaccine Safety Datalink. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States. Neurology 2014;83:1823-30. [PMID: 25320099 DOI: 10.1212/WNL.0000000000000987] [Cited by in Crossref: 51] [Cited by in F6Publishing: 18] [Article Influence: 6.4] [Reference Citation Analysis]
86 Liu Z, Yu L, Gu P, Bo R, Xu S, Wusiman A, Liu J, Hu Y, Wang D. Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo. Int J Nanomedicine 2020;15:8595-608. [PMID: 33177820 DOI: 10.2147/IJN.S266165] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Ahmed SS, Schur PH, Macdonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. Journal of Autoimmunity 2014;50:1-11. [DOI: 10.1016/j.jaut.2014.01.033] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 11.5] [Reference Citation Analysis]
88 Seo YB, Moon S, Jeon CH, Song JY, Sung Y, Jeong SJ, Kwon KT, Kim ES, Kim J, Kim H, Park D, Park S, Park JK, Ahn JK, Oh JS, Yun JW, Lee J, Lee HY, Choi MJ, Choi WS, Choi YH, Choi J, Heo JY, Cheong HJ, Lee S. The Practice Guideline for Vaccinating Korean Patients With Autoimmune Inflammatory Rheumatic Disease. J Rheum Dis 2020;27:182-202. [DOI: 10.4078/jrd.2020.27.3.182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Chua BY, Brown LE, Jackson DC. Considerations for the rapid deployment of vaccines against H7N9 influenza. Expert Rev Vaccines 2014;13:1327-37. [PMID: 25017993 DOI: 10.1586/14760584.2014.938641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
90 Treanor JJ. Prospects for broadly protective influenza vaccines. Vaccine 2015;33:D39-45. [DOI: 10.1016/j.vaccine.2015.08.053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
91 Czako R, Subbarao K. Refining the approach to vaccines against influenza A viruses with pandemic potential. Future Virol 2015;10:1033-47. [PMID: 26587050 DOI: 10.2217/fvl.15.69] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
92 De Serres G, Rouleau I, Skowronski DM, Ouakki M, Lacroix K, Bédard F, Toth E, Landry M, Dupré N. Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors. Vaccine 2015;33:4464-71. [DOI: 10.1016/j.vaccine.2015.07.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
93 Guo J, Yang Y, Xiao W, Sun W, Yu H, Du L, Lustigman S, Jiang S, Kou Z, Zhou Y. A truncated fragment of Ov-ASP-1 consisting of the core pathogenesis-related-1 (PR-1) domain maintains adjuvanticity as the full-length protein. Vaccine 2015;33:1974-80. [PMID: 25736195 DOI: 10.1016/j.vaccine.2015.02.053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
94 Destefano F, Offit PA, Fisher A. Vaccine Safety. Plotkin's Vaccines. Elsevier; 2018. pp. 1584-1600.e10. [DOI: 10.1016/b978-0-323-35761-6.00082-1] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
95 Arango M, Kivity S, Shoenfeld Y. Is narcolepsy a classical autoimmune disease? Pharmacological Research 2015;92:6-12. [DOI: 10.1016/j.phrs.2014.10.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
96 Saariaho AH, Vuorela A, Freitag TL, Pizza F, Plazzi G, Partinen M, Vaarala O, Meri S. Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. J Autoimmun 2015;63:68-75. [PMID: 26227560 DOI: 10.1016/j.jaut.2015.07.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
97 Harris T, Wong K, Stanford L, Fediurek J, Crowcroft N, Deeks S. Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data. Euro Surveill 2014;19:20900. [PMID: 25232921 DOI: 10.2807/1560-7917.es2014.19.36.20900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
98 Wallenius M, Lind A, Akel O, Karlsson E, Svensson M, Arvidsson E, Ramelius A, Törn C, Palm L, Lernmark Å, Elding Larsson H. Autoantibodies in Pandemrix®-induced narcolepsy: Nine candidate autoantigens fail the conformational autoantibody test. Autoimmunity 2019;52:185-91. [PMID: 31328572 DOI: 10.1080/08916934.2019.1643843] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
99 Nafziger AN, Pratt DS. Seasonal influenza vaccination and technologies. J Clin Pharmacol 2014;54:719-31. [PMID: 24691877 DOI: 10.1002/jcph.299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
100 Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber J, D'Ancona F, Levy-Bruhl D, Dematte L, Giambi C, Valentiner-Branth P, Stankiewicz I, Appelgren E, O Flanagan D; VENICE project gatekeepers group. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Euro Surveill 2014;19:20780. [PMID: 24786262 DOI: 10.2807/1560-7917.es2014.19.16.20780] [Cited by in Crossref: 102] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
101 Ferner RE, Mcgettigan P. Adverse drug reactions. BMJ. [DOI: 10.1136/bmj.k4051] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
102 i Vila TF. Flu Vaccination: The Gap Between Evidence and Public Policy. Int J Health Serv 2015;45:453-70. [DOI: 10.1177/0020731415585976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Pebody R, Mcmenamin J, Nohynek H. Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere. Arch Dis Child 2017;103:101-5. [DOI: 10.1136/archdischild-2016-312165] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
104 Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol 2013;21:350-8. [PMID: 23685068 DOI: 10.1016/j.tim.2013.04.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
105 He D, Zhang H, Xiao J, Zhang X, Xie M, Pan D, Wang M, Luo X, Bu B, Zhang M, Wang W. Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis. Ann Neurol 2018;84:386-400. [PMID: 30246904 DOI: 10.1002/ana.25267] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
106 Mastelic B, Garçon N, Del Giudice G, Golding H, Gruber M, Neels P, Fritzell B. Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biologicals 2013;41:458-68. [PMID: 24071553 DOI: 10.1016/j.biologicals.2013.08.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
107 Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014;14:227-38. [PMID: 24360892 DOI: 10.1016/S1473-3099(13)70238-X] [Cited by in Crossref: 62] [Cited by in F6Publishing: 23] [Article Influence: 6.9] [Reference Citation Analysis]
108 Ljung R, Sundström A, Grünewald M, Backman C, Feltelius N, Gedeborg R, Zethelius B. The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Ups J Med Sci 2021;126. [PMID: 34984096 DOI: 10.48101/ujms.v126.8136] [Reference Citation Analysis]
109 Chen X, Wang J, Shah D, Wu MX. An update on the use of laser technology in skin vaccination. Expert Rev Vaccines 2013;12:1313-23. [PMID: 24127871 DOI: 10.1586/14760584.2013.844070] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
110 Brito LA, O'hagan DT. Designing and building the next generation of improved vaccine adjuvants. Journal of Controlled Release 2014;190:563-79. [DOI: 10.1016/j.jconrel.2014.06.027] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 13.0] [Reference Citation Analysis]
111 Meskus M, Oikkonen V. Embodied material encounters and the ambiguous promise of biomedical futures: The case of biologically derived medicines. New Genetics and Society 2020;39:441-58. [DOI: 10.1080/14636778.2020.1778459] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, Lim FS, de Los Santos AM, Weber MA, Tinoco JC, Mezerville MH, Faingezicht I, Kosuwon P, Lopez P, Borja-Tabora C, Li P, Durviaux S, Fries L, Dubin G, Breuer T, Innis BL, Vaughn DW. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis 2014;210:545-57. [PMID: 24652494 DOI: 10.1093/infdis/jiu173] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
113 Brito LA, Malyala P, O'Hagan DT. Vaccine adjuvant formulations: a pharmaceutical perspective. Semin Immunol 2013;25:130-45. [PMID: 23850011 DOI: 10.1016/j.smim.2013.05.007] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 8.7] [Reference Citation Analysis]
114 Song JH, Kim TW, Um YH, Hong SC. Narcolepsy: Association with H1N1 Infection and Vaccination. Sleep Med Res 2016;7:43-7. [DOI: 10.17241/smr.2016.00101] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
115 Shah RR, Hassett KJ, Brito LA. Overview of Vaccine Adjuvants: Introduction, History, and Current Status. In: Fox CB, editor. Vaccine Adjuvants. New York: Springer; 2017. pp. 1-13. [DOI: 10.1007/978-1-4939-6445-1_1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
116 Winstone AM, Stellitano L, Verity C, Andrews N, Miller E, Stowe J, Shneerson J. Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England. Dev Med Child Neurol 2014;56:1117-23. [PMID: 25041214 DOI: 10.1111/dmcn.12522] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
117 Honda-Okubo Y, Saade F, Petrovsky N. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 2012;30:5373-81. [PMID: 22728225 DOI: 10.1016/j.vaccine.2012.06.021] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 10.6] [Reference Citation Analysis]
118 van der Most R, Van Mechelen M, Destexhe E, Wettendorff M, Hanon E. Narcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal. Hum Vaccin Immunother 2014;10:572-6. [PMID: 24342916 DOI: 10.4161/hv.27412] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
119 Brillo E, Tosto V, Giardina I, Buonomo E. Maternal tetanus, diphtheria, and acellular pertussis (Tdap) and influenza immunization: an overview. J Matern Fetal Neonatal Med 2021;34:3415-44. [PMID: 31645152 DOI: 10.1080/14767058.2019.1680633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
120 Choe YJ, Bae G, Lee D. No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: An ecological study. Vaccine 2012;30:7439-42. [DOI: 10.1016/j.vaccine.2012.10.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
121 Wijnans L, Dodd C, de Ridder M, Romio S, Weibel D, Overeem S, Lammers GJ, Bonhoeffer J, Black S, Sturkenboom M. Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias. Expert Rev Vaccines 2016;15:573-84. [PMID: 26967200 DOI: 10.1586/14760584.2016.1164045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
122 Nellore A, Randall TD. Narcolepsy and influenza vaccination-the inappropriate awakening of immunity. Ann Transl Med 2016;4:S29. [PMID: 27867997 DOI: 10.21037/atm.2016.10.60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
123 Lind A, Freyhult E, Ramelius A, Olsson T, Arnheim-Dahlström L, Lamb F, Khademi M, Ambati A, Maeurer M, Lima Bomfim I, Fink K, Fex M, Törn C, Elding Larsson H, Lernmark Å. Antibody Affinity Against 2009 A/H1N1 Influenza and Pandemrix Vaccine Nucleoproteins Differs Between Childhood Narcolepsy Patients and Controls. Viral Immunol 2017;30:590-600. [PMID: 28796576 DOI: 10.1089/vim.2017.0066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
124 Treanor JJ. Prospects for Broadly Protective Influenza Vaccines. Am J Prev Med 2015;49:S355-63. [PMID: 26590435 DOI: 10.1016/j.amepre.2015.09.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
125 Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: Shifting to better vaccines. Vaccine 2016;34:2926-33. [PMID: 27038130 DOI: 10.1016/j.vaccine.2016.03.085] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 13.8] [Reference Citation Analysis]
126 Dhanda S, Osborne V, Lynn E, Shakir S. Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK? BMJ Evid Based Med 2020:bmjebm-2020-111507. [PMID: 33087452 DOI: 10.1136/bmjebm-2020-111507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
127 Johansen K, Brasseur D, Macdonald N, Nohynek H, Vandeputte J, Wood D, Neels P. Where are we in our understanding of the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines? Biologicals 2016;44:276-80. [DOI: 10.1016/j.biologicals.2016.04.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
128 Barclay T, Petrovsky N. Vaccine Adjuvant Nanotechnologies. Micro and Nanotechnology in Vaccine Development. Elsevier; 2017. pp. 127-47. [DOI: 10.1016/b978-0-323-39981-4.00007-5] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
129 Natori Y, Sasaki E, Soeda S, Furukawa S, Azami Y, Tokuda E, Kanbayashi T, Saji S. Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab. J Immunother Cancer 2020;8:e001164. [PMID: 33004543 DOI: 10.1136/jitc-2020-001164] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Dramé M, Vaughn DW, Schuind A. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study. Vaccine 2015;33:2800-7. [PMID: 25910919 DOI: 10.1016/j.vaccine.2015.04.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
131 O’flanagan D, Barret AS, Foley M, Cotter S, Bonner C, Crowe C, Lynch B, Sweeney B, Johnson H, Mccoy B, Purcell E. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Eurosurveillance 2014;19. [DOI: 10.2807/1560-7917.es2014.19.17.20789] [Cited by in Crossref: 42] [Article Influence: 5.3] [Reference Citation Analysis]
132 Helanterä I, Anttila VJ, Lappalainen M, Lempinen M, Isoniemi H. Outbreak of Influenza A(H1N1) in a Kidney Transplant Unit-Protective Effect of Vaccination. Am J Transplant 2015;15:2470-4. [PMID: 25943587 DOI: 10.1111/ajt.13285] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
133 Magnus P, Gunnes N, Tveito K, Bakken IJ, Ghaderi S, Stoltenberg C, Hornig M, Lipkin WI, Trogstad L, Håberg SE. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine 2015;33:6173-7. [PMID: 26475444 DOI: 10.1016/j.vaccine.2015.10.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
134 Bernard-Valnet R, Yshii L, Quériault C, Nguyen XH, Arthaud S, Rodrigues M, Canivet A, Morel AL, Matthys A, Bauer J, Pignolet B, Dauvilliers Y, Peyron C, Liblau RS. CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc Natl Acad Sci U S A 2016;113:10956-61. [PMID: 27621438 DOI: 10.1073/pnas.1603325113] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 12.2] [Reference Citation Analysis]
135 Li L, Honda-Okubo Y, Li C, Sajkov D, Petrovsky N. Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine. PLoS One 2015;10:e0132003. [PMID: 26177480 DOI: 10.1371/journal.pone.0132003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
136 Nakahashi-Ouchida R, Yuki Y, Kiyono H. Development of a nanogel-based nasal vaccine as a novel antigen delivery system. Expert Rev Vaccines 2017;16:1231-40. [PMID: 29053938 DOI: 10.1080/14760584.2017.1395702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
137 Kemmeren J, Honsbeek M, Dijkstra F, de Lange M, van der Maas N, Smallenburg R, Koppeschaar C, van der Hoek W. Comparison of different collection methods for reported adverse events following pandemic and seasonal influenza vaccination. Vaccine 2016;34:3961-6. [PMID: 27349839 DOI: 10.1016/j.vaccine.2016.06.055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Aoshi T. Modes of Action for Mucosal Vaccine Adjuvants. Viral Immunol 2017;30:463-70. [PMID: 28436755 DOI: 10.1089/vim.2017.0026] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
139 Chen YH, Huang YS, Chen CH. Increased plasma level of tumor necrosis factor α in patients with narcolepsy in Taiwan. Sleep Med 2013;14:1272-6. [PMID: 24157100 DOI: 10.1016/j.sleep.2013.04.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
140 Shoenfeld Y. Video Q&A: what is ASIA? An interview with Yehuda Shoenfeld. BMC Med 2013;11:118. [PMID: 23635355 DOI: 10.1186/1741-7015-11-118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
141 Gruber MF, Marshall VB. Regulation and Testing of Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 1547-1565.e2. [DOI: 10.1016/b978-0-323-35761-6.00079-1] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
142 Caster O, Norén GN, Edwards IR. Computing limits on medicine risks based on collections of individual case reports. Theor Biol Med Model 2014;11:15. [PMID: 24661640 DOI: 10.1186/1742-4682-11-15] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
143 Talaat KR, Halsey NA, Cox AB, Coles CL, Durbin AP, Ramakrishnan A, Bream JH. Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination. Influenza Other Respir Viruses 2018;12:202-10. [PMID: 28991404 DOI: 10.1111/irv.12509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
144 Pompano RR, Chen J, Verbus EA, Han H, Fridman A, McNeely T, Collier JH, Chong AS. Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs. Adv Healthc Mater 2014;3:1898-908. [PMID: 24923735 DOI: 10.1002/adhm.201400137] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 10.5] [Reference Citation Analysis]
145 Deerhake ME, Barclay WE, Shinohara ML. Are Neuropeptide-Reactive T Cells behind Narcolepsy? Immunity 2018;49:796-8. [PMID: 30462995 DOI: 10.1016/j.immuni.2018.11.002] [Reference Citation Analysis]
146 Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M, Schwarz TF, Watanveerade V, Wenzel JJ, Zalcman G, Bambure V, Li P, Caplanusi A, Madan A, Gillard P, Vaughn DW. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infect Dis 2013;13:435. [PMID: 24041010 DOI: 10.1186/1471-2334-13-435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
147 Scheer D, Schwartz SW, Parr M, Zgibor J, Sanchez-Anguiano A, Rajaram L. Prevalence and incidence of narcolepsy in a US health care claims database, 2008-2010. Sleep 2019;42:zsz091. [PMID: 31004158 DOI: 10.1093/sleep/zsz091] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
148 Lugnér AK, van Boven M, de Vries R, Postma MJ, Wallinga J. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ 2012;345:e4445. [PMID: 22791791 DOI: 10.1136/bmj.e4445] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
149 Tedjasukmana R. Sleep Disturbances Linked to Genetic Disorders. Sleep Medicine Clinics 2022. [DOI: 10.1016/j.jsmc.2021.10.005] [Reference Citation Analysis]
150 Nevsimalova S. The Diagnosis and Treatment of Pediatric Narcolepsy. Curr Neurol Neurosci Rep 2014;14. [DOI: 10.1007/s11910-014-0469-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
151 Nguyen QT, Kim E, Yang J, Lee C, Ha DH, Lee CG, Lee YR, Poo H. E. coli-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine. Vaccines (Basel) 2020;8:E306. [PMID: 32560094 DOI: 10.3390/vaccines8020306] [Reference Citation Analysis]
152 Plotkin SA, Offit PA, DeStefano F, Larson HJ, Arora NK, Zuber PLF, Fombonne E, Sejvar J, Lambert PH, Hviid A, Halsey N, Garçon N, Peden K, Pollard AJ, Markowitz LE, Glanz J. The science of vaccine safety: Summary of meeting at Wellcome Trust. Vaccine 2020;38:1869-80. [PMID: 31987690 DOI: 10.1016/j.vaccine.2020.01.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
153 O’hagan DT, Fox CB. Are we entering a new age for human vaccine adjuvants? Expert Review of Vaccines 2015;14:909-11. [DOI: 10.1586/14760584.2015.1043273] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
154 Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 2013;8:360-76. [PMID: 23316023 DOI: 10.1002/cmdc.201200487] [Cited by in Crossref: 205] [Cited by in F6Publishing: 195] [Article Influence: 22.8] [Reference Citation Analysis]
155 Pizza F, Peltola H, Sarkanen T, Moghadam KK, Plazzi G, Partinen M. Childhood narcolepsy with cataplexy: comparison between post-H1N1 vaccination and sporadic cases. Sleep Medicine 2014;15:262-5. [DOI: 10.1016/j.sleep.2013.09.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
156 Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013;12:747-58. [PMID: 23885820 DOI: 10.1586/14760584.2013.811188] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 11.0] [Reference Citation Analysis]
157 Kuusisalo S, Koivunen JP, Iivanainen S. Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study. Cancers (Basel) 2022;14:2276. [PMID: 35565405 DOI: 10.3390/cancers14092276] [Reference Citation Analysis]
158 Gauci S, Hosking W, Bruck D, Schumacher U. Narcolepsy, cataplexy, hypocretin and co-existing other health complaints: A review. Cogent Medicine 2017;4:1312791. [DOI: 10.1080/2331205x.2017.1312791] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
159 Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol 2015;14:318-28. [PMID: 25728441 DOI: 10.1016/S1474-4422(14)70218-2] [Cited by in Crossref: 107] [Cited by in F6Publishing: 34] [Article Influence: 15.3] [Reference Citation Analysis]
160 Davis EM, Ramani C, Quigg M. Neurologic Manifestations of Systemic Disease: Sleep Disorders. Curr Treat Options Neurol 2020;22:30. [PMID: 32834712 DOI: 10.1007/s11940-020-00639-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
161 Ludwig B, Smith S, Heussler H. Associations Between Neuropsychological, Neurobehavioral and Emotional Functioning and Either Narcolepsy or Idiopathic Hypersomnia in Children and Adolescents. J Clin Sleep Med 2018;14:661-74. [PMID: 29609710 DOI: 10.5664/jcsm.7066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
162 Wutzler P, Hardt R, Knuf M, Wahle K. Targeted vaccine selection in influenza vaccination. Dtsch Arztebl Int 2013;110:793-8. [PMID: 24314622 DOI: 10.3238/arztebl.2013.0793] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
163 Mohn KG, Zhou F. Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of View. Vaccines (Basel) 2018;6:E32. [PMID: 29861454 DOI: 10.3390/vaccines6020032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
164 Masoudi S, Ploen D, Kunz K, Hildt E. The adjuvant component α-tocopherol triggers via modulation of Nrf2 the expression and turnover of hypocretin in vitro and its implication to the development of narcolepsy. Vaccine 2014;32:2980-8. [PMID: 24721530 DOI: 10.1016/j.vaccine.2014.03.085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
165 Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013;19:1597-608. [PMID: 24309663 DOI: 10.1038/nm.3409] [Cited by in Crossref: 675] [Cited by in F6Publishing: 641] [Article Influence: 75.0] [Reference Citation Analysis]
166 Berlanda Scorza F. Advancing new vaccines against pandemic influenza in low-resource countries. Vaccine 2017;35:5397-402. [DOI: 10.1016/j.vaccine.2017.03.094] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
167 Han F, Faraco J, Dong XS, Ollila HM, Lin L, Li J, An P, Wang S, Jiang KW, Gao ZC, Zhao L, Yan H, Liu YN, Li QH, Zhang XZ, Hu Y, Wang JY, Lu YH, Lu CJ, Zhou W, Hallmayer J, Huang YS, Strohl KP, Pollmächer T, Mignot E. Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet 2013;9:e1003880. [PMID: 24204295 DOI: 10.1371/journal.pgen.1003880] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 10.8] [Reference Citation Analysis]
168 Brodin P, Valentini D, Uhlin M, Mattsson J, Zumla A, Maeurer MJ. Systems level immune response analysis and personalized medicine. Expert Review of Clinical Immunology 2014;9:307-17. [DOI: 10.1586/eci.13.9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
169 Lopalco PL, DeStefano F. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine 2015;33:1541-8. [PMID: 25444788 DOI: 10.1016/j.vaccine.2014.10.047] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
170 Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses 2019;11:E762. [PMID: 31430946 DOI: 10.3390/v11080762] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 29.7] [Reference Citation Analysis]
171 Feng H, Yamashita M, da Silva Lopes TJ, Watanabe T, Kawaoka Y. Injectable Excipients as Novel Influenza Vaccine Adjuvants. Front Microbiol 2019;10:19. [PMID: 30733711 DOI: 10.3389/fmicb.2019.00019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
172 Hovi M, Heiskala H, Aronen ET, Saarenpää-Heikkilä O, Olsen P, Nokelainen P, Kirjavainen T. Finnish children who experienced narcolepsy after receiving the Pandemrix vaccine during the 2009-2010 H1N1 pandemic demonstrated high level of psychosocial problems. Acta Paediatr 2022;111:850-8. [PMID: 34932852 DOI: 10.1111/apa.16233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, Shoenfeld Y. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013;32:1301-7. [PMID: 23624585 DOI: 10.1007/s10067-013-2266-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 58] [Article Influence: 8.2] [Reference Citation Analysis]
174 Bollaerts K, Shinde V, Dos Santos G, Ferreira G, Bauchau V, Cohet C, Verstraeten T. Application of Probabilistic Multiple-Bias Analyses to a Cohort- and a Case-Control Study on the Association between Pandemrix™ and Narcolepsy. PLoS One 2016;11:e0149289. [PMID: 26901063 DOI: 10.1371/journal.pone.0149289] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
175 Fox CB, Huynh C, O’hara MK, Onu A. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine 2013;31:1633-40. [DOI: 10.1016/j.vaccine.2012.10.048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
176 Halsey NA, Talaat KR, Greenbaum A, Mensah E, Dudley MZ, Proveaux T, Salmon DA. The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. Vaccine 2015;33 Suppl 5:F1-F67. [PMID: 26822822 DOI: 10.1016/j.vaccine.2015.10.080] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
177 Genito CJ, Batty CJ, Bachelder EM, Ainslie KM. Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases. Adv Nanobiomed Res 2021;:2000041. [PMID: 33681864 DOI: 10.1002/anbr.202000041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
178 Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 2014;13:600-13. [PMID: 24849861 DOI: 10.1016/S1474-4422(14)70075-4] [Cited by in Crossref: 173] [Cited by in F6Publishing: 60] [Article Influence: 21.6] [Reference Citation Analysis]
179 Lacroix C, Mallaret M, Jonville-bera A. Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres. Therapies 2020;75:207-13. [DOI: 10.1016/j.therap.2020.02.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, Mignot E, De Wals P. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One 2014;9:e108489. [PMID: 25264897 DOI: 10.1371/journal.pone.0108489] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
181 Miyagawa T, Tokunaga K. Genetics of narcolepsy. Hum Genome Var 2019;6:4. [PMID: 30652006 DOI: 10.1038/s41439-018-0033-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
182 Cadusseau J, Ragunathan-Thangarajah N, Surenaud M, Hue S, Authier FJ, Gherardi RK. Selective elevation of circulating CCL2/MCP1 levels in patients with longstanding post-vaccinal macrophagic myofasciitis and ASIA. Curr Med Chem 2014;21:511-7. [PMID: 24083602 DOI: 10.2174/09298673113206660287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
183 Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R. Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin Biol Ther 2013;13:121-35. [PMID: 23189937 DOI: 10.1517/14712598.2013.748030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
184 Kippola-Pääkkönen A, Härkäpää K, Valkonen J, Tuulio-Henriksson A, Autti-Rämö I. Psychosocial intervention for children with narcolepsy:: Parents' expectations and perceived support. J Child Health Care 2016;20:521-9. [PMID: 27091954 DOI: 10.1177/1367493516643420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
185 Ambati A, Luo G, Pradhan E, Louis J, Lin L, Leib RD, Ollila HM, Poiret T, Adams C, Mignot E. Mass Spectrometric Characterization of Narcolepsy-Associated Pandemic 2009 Influenza Vaccines. Vaccines (Basel) 2020;8:E630. [PMID: 33142956 DOI: 10.3390/vaccines8040630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Gianchecchi E, Trombetta C, Piccirella S, Montomoli E. Evaluating influenza vaccines: progress and perspectives. Future Virology 2016;11:379-93. [DOI: 10.2217/fvl-2016-0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
187 Ravel JM, Mignot EJM. [Narcolepsy: From the discovery of a wake promoting peptide to autoimmune T cell biology and molecular mimicry with flu epitopes]. Biol Aujourdhui 2019;213:87-108. [PMID: 31829930 DOI: 10.1051/jbio/2019026] [Reference Citation Analysis]
188 Domínguez A, Godoy P, Torner N. The Effectiveness of Influenza Vaccination in Different Groups. Expert Rev Vaccines 2016;15:751-64. [PMID: 26775669 DOI: 10.1586/14760584.2016.1142878] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
189 Tafti M, Hor H, Dauvilliers Y, Lammers GJ, Overeem S, Mayer G, Javidi S, Iranzo A, Santamaria J, Peraita-Adrados R, Vicario JL, Arnulf I, Plazzi G, Bayard S, Poli F, Pizza F, Geisler P, Wierzbicka A, Bassetti CL, Mathis J, Lecendreux M, Donjacour CE, van der Heide A, Heinzer R, Haba-Rubio J, Feketeova E, Högl B, Frauscher B, Benetó A, Khatami R, Cañellas F, Pfister C, Scholz S, Billiard M, Baumann CR, Ercilla G, Verduijn W, Claas FH, Dubois V, Nowak J, Eberhard HP, Pradervand S, Hor CN, Testi M, Tiercy JM, Kutalik Z. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 2014;37:19-25. [PMID: 24381371 DOI: 10.5665/sleep.3300] [Cited by in Crossref: 118] [Cited by in F6Publishing: 103] [Article Influence: 14.8] [Reference Citation Analysis]
190 Bonvalet M, Ollila HM, Ambati A, Mignot E. Autoimmunity in narcolepsy. Curr Opin Pulm Med 2017;23:522-9. [PMID: 28991006 DOI: 10.1097/MCP.0000000000000426] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
191 Ssemaganda A, Giddam AK, Zaman M, Skwarczynski M, Toth I, Stanisic DI, Good MF. Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines. Front Immunol 2019;10:135. [PMID: 30774635 DOI: 10.3389/fimmu.2019.00135] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
192 Clegg CH, Roque R, Perrone LA, Rininger JA, Bowen R, Reed SG. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. PLoS One 2014;9:e88979. [PMID: 24551202 DOI: 10.1371/journal.pone.0088979] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
193 Lansbury LE, Smith S, Beyer W, Karamehic E, Pasic-juhas E, Sikira H, Mateus A, Oshitani H, Zhao H, Beck CR, Nguyen-van-tam JS. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis. Vaccine 2017;35:1996-2006. [DOI: 10.1016/j.vaccine.2017.02.059] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
194 Nguyen QT, Choi YK. Targeting Antigens for Universal Influenza Vaccine Development. Viruses 2021;13:973. [PMID: 34073996 DOI: 10.3390/v13060973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Roßmann L, Bagola K, Stephen T, Gerards AL, Walber B, Ullrich A, Schülke S, Kamp C, Spreitzer I, Hasan M, David-Watine B, Shorte SL, Bastian M, van Zandbergen G. Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response. Proc Natl Acad Sci U S A 2021;118:e2103651118. [PMID: 34561306 DOI: 10.1073/pnas.2103651118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Lind A, Akel O, Wallenius M, Ramelius A, Maziarz M, Zhao LP, Geraghty DE, Palm L, Lernmark Å, Larsson HE. HLA high-resolution typing by next-generation sequencing in Pandemrix-induced narcolepsy. PLoS One 2019;14:e0222882. [PMID: 31577807 DOI: 10.1371/journal.pone.0222882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
197 Bond M, Bechter K, Müller N, Tebartz van Elst L, Meier UC. A role for pathogen risk factors and autoimmunity in encephalitis lethargica? Prog Neuropsychopharmacol Biol Psychiatry 2021;109:110276. [PMID: 33549696 DOI: 10.1016/j.pnpbp.2021.110276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Haviari S, Bénet T, Saadatian-Elahi M, André P, Loulergue P, Vanhems P. Vaccination of healthcare workers: A review. Hum Vaccin Immunother 2015;11:2522-37. [PMID: 26291642 DOI: 10.1080/21645515.2015.1082014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 10.3] [Reference Citation Analysis]
199 Rowhani-Rahbar A, Klein NP, Baxter R. Assessing the safety of influenza vaccination in specific populations: children and the elderly. Expert Rev Vaccines 2012;11:973-84. [PMID: 23002978 DOI: 10.1586/erv.12.66] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
200 Chrapkowska C, Galanis I, Kark M, Lepp T, Lindstrand A, Roth A, Nilsson A. Validation of the new Swedish vaccination register – Accuracy and completeness of register data. Vaccine 2020;38:4104-10. [DOI: 10.1016/j.vaccine.2020.04.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Aydinoz S, Huang YS, Gozal D, Inocente CO, Franco P, Kheirandish-Gozal L. Allergies and Disease Severity in Childhood Narcolepsy: Preliminary Findings. Sleep 2015;38:1981-4. [PMID: 25902808 DOI: 10.5665/sleep.5254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
202 Oberle D, Pavel J, Keller-stanislawski B. Spontaneous reporting of suspected narcolepsy after vaccination against pandemic influenza A (H1N1) in Germany. Pharmacoepidemiol Drug Saf 2017;26:1321-7. [DOI: 10.1002/pds.4292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Sullivan SS. Current treatment of selected pediatric sleep disorders. Neurotherapeutics 2012;9:791-800. [PMID: 23055049 DOI: 10.1007/s13311-012-0149-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
204 Engström M, Hallböök T, Szakacs A, Karlsson T, Landtblom AM. Functional magnetic resonance imaging in narcolepsy and the kleine-levin syndrome. Front Neurol 2014;5:105. [PMID: 25009530 DOI: 10.3389/fneur.2014.00105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
205 Elding Larsson H, Lynch KF, Lönnrot M, Haller MJ, Lernmark Å, Hagopian WA, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Rewers MJ, Hyöty H; TEDDY Study Group. Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children. Diabetologia 2018;61:193-202. [PMID: 28990147 DOI: 10.1007/s00125-017-4448-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
206 Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, Overeem S. Narcolepsy. Nat Rev Dis Primers 2017;3:16100. [PMID: 28179647 DOI: 10.1038/nrdp.2016.100] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 21.8] [Reference Citation Analysis]
207 Poland GA, Whitaker JA, Poland CM, Ovsyannikova IG, Kennedy RB. Vaccinology in the third millennium: scientific and social challenges. Curr Opin Virol 2016;17:116-25. [PMID: 27039875 DOI: 10.1016/j.coviro.2016.03.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
208 Lind A, Eriksson D, Akel O, Ramelius A, Palm L, Lernmark Å, Kämpe O, Elding Larsson H, Landegren N. Screening for autoantibody targets in post-vaccination narcolepsy using proteome arrays. Scand J Immunol 2020;91:e12864. [PMID: 32056243 DOI: 10.1111/sji.12864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, Hublin C, Linna M, Olsén P, Nokelainen P, Alén R, Wallden T, Espo M, Rusanen H, Olme J, Sätilä H, Arikka H, Kaipainen P, Julkunen I, Kirjavainen T. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012;7:e33723. [PMID: 22470463 DOI: 10.1371/journal.pone.0033723] [Cited by in Crossref: 295] [Cited by in F6Publishing: 232] [Article Influence: 29.5] [Reference Citation Analysis]
210 Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members. Operation Warp Speed: implications for global vaccine security. Lancet Glob Health 2021;9:e1017-21. [PMID: 33780663 DOI: 10.1016/S2214-109X(21)00140-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
211 Hansen OB, Rodrigues A, Martins C, Rieckmann A, Benn CS, Aaby P, Fisker AB. Impact of H1N1 Influenza Vaccination on Child Morbidity in Guinea-Bissau. J Trop Pediatr 2019;65:446-56. [PMID: 30590828 DOI: 10.1093/tropej/fmy075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018;15:586-94. [PMID: 29503439 DOI: 10.1038/cmi.2017.151] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 11.5] [Reference Citation Analysis]
213 Grund S, Wichmann O, Mertens T, Hengel H. [Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013;56:76-86. [PMID: 23275959 DOI: 10.1007/s00103-012-1590-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
214 Lunde HM, Bjorvatn B, Myhr KM, Bø L. Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. Acta Neurol Scand Suppl 2013;:24-30. [PMID: 23190288 DOI: 10.1111/ane.12046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
215 Trombetta CM, Gianchecchi E, Montomoli E. Influenza vaccines: Evaluation of the safety profile. Hum Vaccin Immunother 2018;14:657-70. [PMID: 29297746 DOI: 10.1080/21645515.2017.1423153] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
216 De la Herrán-Arita AK, García-García F. Narcolepsy as an immune-mediated disease. Sleep Disord 2014;2014:792687. [PMID: 24551456 DOI: 10.1155/2014/792687] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
217 Cutillo G, Saariaho AH, Meri S. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cell Mol Immunol 2020;17:313-22. [PMID: 32152553 DOI: 10.1038/s41423-020-0388-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
218 Thakur KT, Epstein S, Bilski A, Balbi A, Boehme AK, Brannagan TH, Wesley SF, Riley CS. Neurologic Safety Monitoring of COVID-19 Vaccines: Lessons From the Past to Inform the Present. Neurology 2021;97:767-75. [PMID: 34475124 DOI: 10.1212/WNL.0000000000012703] [Reference Citation Analysis]
219 Moise L, Beseme S, Tassone R, Liu R, Kibria F, Terry F, Martin W, De Groot AS. T cell epitope redundancy: cross-conservation of the TCR face between pathogens and self and its implications for vaccines and autoimmunity. Expert Rev Vaccines 2016;15:607-17. [PMID: 26588466 DOI: 10.1586/14760584.2016.1123098] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
220 Martinez-Orozco FJ, Vicario JL, De Andres C, Fernandez-Arquero M, Peraita-Adrados R. Comorbidity of Narcolepsy Type 1 With Autoimmune Diseases and Other Immunopathological Disorders: A Case-Control Study. J Clin Med Res 2016;8:495-505. [PMID: 27298657 DOI: 10.14740/jocmr2569w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
221 Oikkonen V. The 2009 H1N1 pandemic, vaccine-associated narcolepsy, and the politics of risk and harm. Health (London). [DOI: 10.1177/1363459320925880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
222 Melén K, Partinen M, Tynell J, Sillanpää M, Himanen SL, Saarenpää-Heikkilä O, Hublin C, Olsen P, Ilonen J, Nohynek H, Syrjänen R, Kilpi T, Vuorela A, Kirjavainen T, Vaarala O, Julkunen I. No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. PLoS One 2013;8:e68402. [PMID: 23950869 DOI: 10.1371/journal.pone.0068402] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
223 Lind A, Marzinotto I, Brigatti C, Ramelius A, Piemonti L, Lampasona V. A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis. Sci Rep 2021;11:4063. [PMID: 33603024 DOI: 10.1038/s41598-021-83543-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
224 Nanishi E, Dowling DJ, Levy O. Toward precision adjuvants: optimizing science and safety. Curr Opin Pediatr 2020;32:125-38. [PMID: 31904601 DOI: 10.1097/MOP.0000000000000868] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 12.5] [Reference Citation Analysis]
225 Ollila HM. Narcolepsy type 1: what have we learned from genetics? Sleep 2020;43:zsaa099. [PMID: 32442260 DOI: 10.1093/sleep/zsaa099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
226 Mignot EJ. History of narcolepsy at Stanford University. Immunol Res 2014;58:315-39. [PMID: 24825774 DOI: 10.1007/s12026-014-8513-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
227 Aps LRMM, Piantola MAF, Pereira SA, Castro JT, Santos FAO, Ferreira LCS. Adverse events of vaccines and the consequences of non-vaccination: a critical review. Rev Saude Publica 2018;52:40. [PMID: 29668817 DOI: 10.11606/s1518-8787.2018052000384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
228 O'hagan DT, Tsai TF, Brito LA. Emulsion based vaccine adjuvants. Human Vaccines & Immunotherapeutics 2014;9:1698-700. [DOI: 10.4161/hv.24829] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
229 Luo G, Yogeshwar S, Lin L, Mignot EJ. T cell reactivity to regulatory factor X4 in type 1 narcolepsy. Sci Rep 2021;11:7841. [PMID: 33837283 DOI: 10.1038/s41598-021-87481-8] [Reference Citation Analysis]
230 Thebault S, Vincent A, Gringras P. Narcolepsy and H1N1 vaccination: a link? Current Opinion in Pulmonary Medicine 2013;19:587-93. [DOI: 10.1097/mcp.0b013e328365af97] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
231 McClymont E, Brophy J, Dubey V, Kwong J, Meyer S, Crowcroft N, Halperin S, MacDonald S, Simmons K, Top K, Ward B, Sadarangani M. Is 'conflict of interest' a Misnomer? Managing interests in immunization research and evaluation. Hum Vaccin Immunother 2021;:1-6. [PMID: 33651972 DOI: 10.1080/21645515.2021.1879580] [Reference Citation Analysis]
232 Stowe J, Andrews N, Miller E. Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy. CNS Drugs 2020;34:1-8. [PMID: 31576507 DOI: 10.1007/s40263-019-00670-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
233 Smith LR, Wodal W, Crowe BA, Kerschbaum A, Bruehl P, Schwendinger MG, Savidis-Dacho H, Sullivan SM, Shlapobersky M, Hartikka J, Rolland A, Barrett PN, Kistner O. Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines. Hum Vaccin Immunother 2013;9:1333-45. [PMID: 23857272 DOI: 10.4161/hv.24209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
234 Gordon DL, Sajkov D, Honda-Okubo Y, Wilks SH, Aban M, Barr IG, Petrovsky N. Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant. Vaccine 2016;34:3780-6. [PMID: 27342914 DOI: 10.1016/j.vaccine.2016.05.071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
235 Lind A, Ramelius A, Olsson T, Arnheim-Dahlström L, Lamb F, Khademi M, Ambati A, Maeurer M, Nilsson AL, Bomfim IL, Fink K, Lernmark Å. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010. J Autoimmun 2014;50:99-106. [PMID: 24485154 DOI: 10.1016/j.jaut.2014.01.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
236 Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccin Immunother 2018;14:550-64. [PMID: 29232151 DOI: 10.1080/21645515.2017.1415684] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 25.8] [Reference Citation Analysis]
237 Mihigo R, Torrealba CV, Coninx K, Nshimirimana D, Kieny MP, Carrasco P, Hedman L, Widdowson M. 2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa—Successes and Challenges. The Journal of Infectious Diseases 2012;206:S22-8. [DOI: 10.1093/infdis/jis535] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
238 Häggmark-Månberg A, Zandian A, Forsström B, Khademi M, Lima Bomfim I, Hellström C, Arnheim-Dahlström L, Hallböök T, Darin N, Lundberg IE, Uhlén M, Partinen M, Schwenk JM, Olsson T, Nilsson P. Autoantibody targets in vaccine-associated narcolepsy. Autoimmunity 2016;49:421-33. [PMID: 27206786 DOI: 10.1080/08916934.2016.1183655] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
239 Luo G, Lin L, Jacob L, Bonvalet M, Ambati A, Plazzi G, Pizza F, Leib R, Adams CM, Partinen M, Mignot EJ. Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases. PLoS One 2017;12:e0187305. [PMID: 29220370 DOI: 10.1371/journal.pone.0187305] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
240 Tsai TF. Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother 2013;45:159-74. [PMID: 24265964 DOI: 10.3947/ic.2013.45.2.159] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
241 Weibel D, Sturkenboom M, Black S, de Ridder M, Dodd C, Bonhoeffer J, Vanrolleghem A, van der Maas N, Lammers GJ, Overeem S, Gentile A, Giglio N, Castellano V, Kwong JC, Murray BJ, Cauch-Dudek K, Juhasz D, Campitelli M, Datta AN, Kallweit U, Huang WT, Huang YS, Hsu CY, Chen HC, Giner-Soriano M, Morros R, Gaig C, Tió E, Perez-Vilar S, Diez-Domingo J, Puertas FJ, Svenson LW, Mahmud SM, Carleton B, Naus M, Arnheim-Dahlström L, Pedersen L, DeStefano F, Shimabukuro TT. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment. Vaccine 2018;36:6202-11. [PMID: 30122647 DOI: 10.1016/j.vaccine.2018.08.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
242 Nguyen XH, Saoudi A, Liblau RS. Vaccine-associated inflammatory diseases of the central nervous system: from signals to causation. Curr Opin Neurol 2016;29:362-71. [PMID: 27023738 DOI: 10.1097/WCO.0000000000000318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
243 Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol 2015;386:151-80. [PMID: 25038938 DOI: 10.1007/82_2014_406] [Cited by in Crossref: 19] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
244 Sarkanen T, Alakuijala A, Julkunen I, Partinen M. Narcolepsy Associated with Pandemrix Vaccine. Curr Neurol Neurosci Rep 2018;18:43. [PMID: 29855798 DOI: 10.1007/s11910-018-0851-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
245 Goodman JL. Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics. Clin Infect Dis 2016;62:495-8. [PMID: 26585520 DOI: 10.1093/cid/civ957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
246 Kashiwagi S, Brauns T, Gelfand J, Poznansky MC. Laser vaccine adjuvants. History, progress, and potential. Hum Vaccin Immunother 2014;10:1892-907. [PMID: 25424797 DOI: 10.4161/hv.28840] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
247 Vaarala O, Vuorela A, Partinen M, Baumann M, Freitag TL, Meri S, Saavalainen P, Jauhiainen M, Soliymani R, Kirjavainen T, Olsen P, Saarenpää-Heikkilä O, Rouvinen J, Roivainen M, Nohynek H, Jokinen J, Julkunen I, Kilpi T. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk. PLoS One 2014;9:e114361. [PMID: 25501681 DOI: 10.1371/journal.pone.0114361] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 9.3] [Reference Citation Analysis]
248 Adam O, Azher S, Valachovic E, Hahn A, Molho E. Narcolepsy genetic marker HLA DQB1*06:02 and excessive daytime sleepiness in Parkinson disease patients treated with dopaminergic agents. J Neurol 2021. [PMID: 34559298 DOI: 10.1007/s00415-021-10813-1] [Reference Citation Analysis]
249 Chen RT, Moro PL, Bauwens J, Bonhoeffer J. Obstetrical and neonatal case definitions for immunization safety data. Vaccine 2016;34:5991-2. [PMID: 27554535 DOI: 10.1016/j.vaccine.2016.08.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
250 Sasaki E, Hamaguchi I, Mizukami T. Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design. Expert Opin Drug Metab Toxicol 2020;16:1051-61. [PMID: 32772723 DOI: 10.1080/17425255.2020.1807936] [Reference Citation Analysis]
251 Granath F, Gedeborg R, Smedje H, Feltelius N. Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine ( P andemrix) during the 2009 H1N1 influenza pandemic. Pharmacoepidemiol Drug Saf 2019;28:1045-53. [DOI: 10.1002/pds.4788] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
252 Fox A, Quinn KM, Subbarao K. Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine. Drugs 2018;78:1297-308. [PMID: 30088204 DOI: 10.1007/s40265-018-0958-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
253 Schlüter B, Schürmann U, Roll C. Häufigkeitszunahme der Narkolepsie im Kindes- und Jugendalter: Fallserie eines pädiatrischen Schlaflabors (1995–2015). Monatsschr Kinderheilkd 2016;164:1103-9. [DOI: 10.1007/s00112-016-0181-0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
254 van der Heide A, Hegeman-Kleinn IM, Peeters E, Lammers GJ, Fronczek R. Immunohistochemical screening for antibodies in recent onset type 1 narcolepsy and after H1N1 vaccination. J Neuroimmunol 2015;283:58-62. [PMID: 26004157 DOI: 10.1016/j.jneuroim.2015.04.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
255 Hoffmann K, Paget J, Wojczewski S, Katic M, Maier M, Soldo D. Influenza vaccination prevalence and demographic factors of patients and GPs in primary care in Austria and Croatia: a cross-sectional comparative study in the framework of the APRES project. Eur J Public Health 2016;26:395-401. [PMID: 26936080 DOI: 10.1093/eurpub/ckw006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
256 Dodd CN, de Ridder M, Huang WT, Weibel D, Giner-Soriano M, Perez-Vilar S, Diez-Domingo J, Svenson LW, Mahmud SM, Carleton B, Naus M, Kwong JC, Murray BJ, Arnheim-Dahlstrom L, Pedersen L, Morros R, Puertas FJ, Black S, Sturkenboom M. Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study. PLoS One 2018;13:e0204799. [PMID: 30332477 DOI: 10.1371/journal.pone.0204799] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
257 Hidalgo H, Kallweit U, Mathis J, Bassetti CL. Post Tick-Borne Encephalitis Virus Vaccination Narcolepsy with Cataplexy. Sleep 2016;39:1811-4. [PMID: 27397572 DOI: 10.5665/sleep.6160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
258 Paules C, Subbarao K. Influenza. Lancet 2017;390:697-708. [PMID: 28302313 DOI: 10.1016/S0140-6736(17)30129-0] [Cited by in Crossref: 307] [Cited by in F6Publishing: 160] [Article Influence: 61.4] [Reference Citation Analysis]
259 Yau ACY, Lönnblom E, Zhong J, Holmdahl R. Influence of hydrocarbon oil structure on adjuvanticity and autoimmunity. Sci Rep 2017;7:14998. [PMID: 29118363 DOI: 10.1038/s41598-017-15096-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
260 Chandler RE. Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events. BMJ 2019;365:l2268. [PMID: 31151960 DOI: 10.1136/bmj.l2268] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
261 Baay M, Bollaerts K, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults. Vaccine 2018;36:4207-14. [PMID: 29885773 DOI: 10.1016/j.vaccine.2018.06.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
262 Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. Nat Med 2019;25:212-20. [PMID: 30692696 DOI: 10.1038/s41591-018-0340-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 18.7] [Reference Citation Analysis]
263 Julkunen I, Partinen M. Neuroimmunology: Disease mechanisms in narcolepsy remain elusive. Nat Rev Neurol 2014;10:616-7. [PMID: 25311588 DOI: 10.1038/nrneurol.2014.191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
264 Plazzi G, Pizza F. Childhood narcolepsy with cataplexy: a newly reported phenotype of an old disease? Sleep Med 2013;14:810-1. [PMID: 23831236 DOI: 10.1016/j.sleep.2013.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
265 Kelly H, Carcione D, Dowse GK, Effler P. The Vaccine-attributable Risk for Febrile Convulsions Following Influenza Vaccine. Pediatric Infectious Disease Journal 2012;31:792. [DOI: 10.1097/inf.0b013e31825686d0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
266 Zhao X, Zhao L, Zhao Y, Huang K, Gong W, Yang Y, Zhao L, Xia X, Li Z, Sheng F, Du X, Jin M. 3-Indoleacetonitrile Is Highly Effective in Treating Influenza A Virus Infection In Vitro and In Vivo. Viruses 2021;13:1433. [PMID: 34452298 DOI: 10.3390/v13081433] [Reference Citation Analysis]
267 Edwards K, Hanquet G, Black S, Mignot E, Jankosky C, Shimabukuro T, Miller E, Nohynek H, Neels P. Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. Biologicals 2019;60:1-7. [PMID: 31130313 DOI: 10.1016/j.biologicals.2019.05.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
268 Mössler C, Groiss F, Wolzt M, Wolschek M, Seipelt J, Muster T. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Vaccine 2013;31:6194-200. [DOI: 10.1016/j.vaccine.2013.10.061] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
269 Korpi ER, Lindholm D, Panula P, Tienari PJ, Haltia M. Finnish neuroscience from past to present. Eur J Neurosci 2020;52:3273-89. [PMID: 32017266 DOI: 10.1111/ejn.14693] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
270 Trogstad L, Bakken IJ, Gunnes N, Ghaderi S, Stoltenberg C, Magnus P, Håberg SE. Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic. Vaccine 2017;35:1879-85. [PMID: 28302408 DOI: 10.1016/j.vaccine.2017.02.053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
271 Shaw CA, Li D, Tomljenovic L. Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy? Immunotherapy 2014;6:1055-71. [DOI: 10.2217/imt.14.81] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
272 Sullivan SG, Price OH, Regan AK. Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations. Ther Adv Vaccines Immunother 2019;7:2515135519826481. [PMID: 30793097 DOI: 10.1177/2515135519826481] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
273 Labombarde JG, Pillai MR, Wehenkel M, Lin CY, Keating R, Brown SA, Crawford JC, Brice DC, Castellaw AH, Mandarano AH, Guy CS, Mejia JR, Lewis CD, Chang TC, Oshansky CM, Wong SS, Webby RJ, Yan M, Li QZ, Marion TN, Thomas PG, McGargill MA. Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity. Cell Rep 2022;38:110482. [PMID: 35263574 DOI: 10.1016/j.celrep.2022.110482] [Reference Citation Analysis]
274 Shimada M, Miyagawa T, Toyoda H, Tokunaga K, Honda M. Epigenome-wide association study of DNA methylation in narcolepsy: an integrated genetic and epigenetic approach. Sleep 2018;41. [PMID: 29425374 DOI: 10.1093/sleep/zsy019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
275 Seong MJ, Hong SB. Autoimmunity and Immunotherapy in Narcolepsy. Sleep Med Res 2017;8:1-7. [DOI: 10.17241/smr.2017.00052] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
276 Maski K, Owens JA. Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management. Lancet Neurol 2016;15:1170-81. [PMID: 27647645 DOI: 10.1016/S1474-4422(16)30204-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
277 Johrden L, Tenbusch M, Lietz R, Bonsmann MS, Niezold T, Wildner O, Bayer W. Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice. Virol J 2013;10:108. [PMID: 23560981 DOI: 10.1186/1743-422X-10-108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
278 Kim YH, Hong KJ, Kim H, Nam JH. Influenza vaccines: Past, present, and future. Rev Med Virol 2021;:e2243. [PMID: 33949021 DOI: 10.1002/rmv.2243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
279 Baum U, Sundman J, Jääskeläinen S, Nohynek H, Puumalainen T, Jokinen J. Establishing and maintaining the National Vaccination Register in Finland. Euro Surveill 2017;22:30520. [PMID: 28488994 DOI: 10.2807/1560-7917.ES.2017.22.17.30520] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
280 Dauvilliers Y, Evangelista E, Lopez R, Barateau L, Scholz S, Crastes de Paulet B, Carlander B, Jaussent I. Vitamin D deficiency in type 1 narcolepsy: a reappraisal. Sleep Medicine 2017;29:1-6. [DOI: 10.1016/j.sleep.2016.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
281 Shimada M, Miyagawa T, Takeshima A, Kakita A, Toyoda H, Niizato K, Oshima K, Tokunaga K, Honda M. Epigenome-wide association study of narcolepsy-affected lateral hypothalamic brains, and overlapping DNA methylation profiles between narcolepsy and multiple sclerosis. Sleep 2020;43:zsz198. [DOI: 10.1093/sleep/zsz198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
282 De la Herrán-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, Macaubas C, Einen M, Plazzi G, Crowe C, Newell EW, Davis MM, Mellins ED, Mignot E. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 2013;5:216ra176. [PMID: 24353159 DOI: 10.1126/scitranslmed.3007762] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 8.8] [Reference Citation Analysis]
283 Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 2021;21:83-100. [PMID: 33353987 DOI: 10.1038/s41577-020-00479-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 64] [Article Influence: 21.5] [Reference Citation Analysis]
284 Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906. [PMID: 24108159 DOI: 10.1136/bmj.f5906] [Cited by in Crossref: 168] [Cited by in F6Publishing: 140] [Article Influence: 18.7] [Reference Citation Analysis]
285 Hendy DA, Amouzougan EA, Young IC, Bachelder EM, Ainslie KM. Nano/microparticle Formulations for Universal Influenza Vaccines. AAPS J 2022;24:24. [PMID: 34997352 DOI: 10.1208/s12248-021-00676-9] [Reference Citation Analysis]
286 Giannoccaro MP, Liguori R, Plazzi G, Pizza F. Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder. Nat Sci Sleep 2021;13:557-77. [PMID: 34007229 DOI: 10.2147/NSS.S275931] [Reference Citation Analysis]
287 Cashman P, Moberley S, Chee K, Stephenson J, Chaverot S, Martinelli J, Gadsden T, Bateman-steel C, Redwood L, Howard Z, Ferson M, Durrheim D. Participant centred safety surveillance of health care workers receiving influenza vaccination. Vaccine 2019;37:2427-9. [DOI: 10.1016/j.vaccine.2019.02.082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
288 Whitaker JA, Ovsyannikova IG, Poland GA. Adversomics: a new paradigm for vaccine safety and design. Expert Rev Vaccines 2015;14:935-47. [PMID: 25937189 DOI: 10.1586/14760584.2015.1038249] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
289 Morcol T, Nagappan P, Bell SJD, Cawthon AG. Influenza A(H5N1) Virus Subunit Vaccine Administered with CaPNP Adjuvant Induce High Virus Neutralization Antibody Titers in Mice. AAPS PharmSciTech 2019;20:315. [PMID: 31591662 DOI: 10.1208/s12249-019-1530-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
290 Beeler JA, Eichelberger MC. Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy. Microb Pathog 2013;55:9-15. [PMID: 23247146 DOI: 10.1016/j.micpath.2012.11.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
291 Alakuijala A, Sarkanen T, Partinen M. Polysomnographic and actigraphic characteristics of patients with H1N1-vaccine-related and sporadic narcolepsy. Sleep Med 2015;16:39-44. [PMID: 25554349 DOI: 10.1016/j.sleep.2014.07.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
292 Arnheim-Dahlström L, Hällgren J, Weibull CE, Sparén P. Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. BMJ 2012;345:e7594. [PMID: 23274350 DOI: 10.1136/bmj.e7594] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
293 Heier M, Gautvik K, Wannag E, Bronder K, Midtlyng E, Kamaleri Y, Storsaeter J. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Medicine 2013;14:867-71. [DOI: 10.1016/j.sleep.2013.03.020] [Cited by in Crossref: 121] [Cited by in F6Publishing: 102] [Article Influence: 13.4] [Reference Citation Analysis]
294 Petrovsky N. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Saf 2015;38:1059-74. [PMID: 26446142 DOI: 10.1007/s40264-015-0350-4] [Cited by in Crossref: 128] [Cited by in F6Publishing: 124] [Article Influence: 21.3] [Reference Citation Analysis]
295 Maletic Neuzil K, Ortiz JR. Influenza Vaccines and Vaccination Strategies. The Vaccine Book. Elsevier; 2016. pp. 423-44. [DOI: 10.1016/b978-0-12-802174-3.00021-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
296 Lindert K, Leav B, Heijnen E, Barrett J, Nicolay U. Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older. International Journal of Infectious Diseases 2019;85:S10-7. [DOI: 10.1016/j.ijid.2019.03.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
297 Singh AK, Mahlios J, Mignot E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun 2013;43:26-31. [PMID: 23497937 DOI: 10.1016/j.jaut.2013.02.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 7.3] [Reference Citation Analysis]
298 Stowe J, Andrews N, Kosky C, Dennis G, Eriksson S, Hall A, Leschziner G, Reading P, Shneerson JM, Donegan K, Miller E. Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England. Sleep 2016;39:1051-7. [PMID: 26856903 DOI: 10.5665/sleep.5752] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
299 Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev 2013;26:476-92. [PMID: 23824369 DOI: 10.1128/CMR.00097-12] [Cited by in Crossref: 193] [Cited by in F6Publishing: 124] [Article Influence: 24.1] [Reference Citation Analysis]
300 Ambati A, Poiret T, Svahn B, Valentini D, Khademi M, Kockum I, Lima I, Arnheim-dahlström L, Lamb F, Fink K, Meng Q, Kumar A, Rane L, Olsson T, Maeurer M. Increased β-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases. J Intern Med 2015;278:264-76. [DOI: 10.1111/joim.12355] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
301 Vesikari T, Richardus JH, Berglund J, Korhonen T, Flodmark C, Lindstrand A, Silfverdal SA, Bambure V, Caplanusi A, Dieussaert I, Roy-ghanta S, Vaughn DW. Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials. Pediatric Infectious Disease Journal 2015;34:774-82. [DOI: 10.1097/inf.0000000000000709] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
302 Vesikari T, Forstén A, Arora A, Tsai T, Clemens R. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine. Hum Vaccin Immunother 2015;11:2102-12. [PMID: 26091244 DOI: 10.1080/21645515.2015.1044167] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
303 Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 2017;152:89-113. [PMID: 26721620 DOI: 10.1016/j.pneurobio.2015.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
304 Spruyt K. Narcolepsy Presentation in Diverse Populations: an Update. Curr Sleep Med Rep 2020;:1-12. [PMID: 33251089 DOI: 10.1007/s40675-020-00195-7] [Reference Citation Analysis]
305 Mignot E. Narcolepsy. Principles and Practice of Sleep Medicine. Elsevier; 2017. pp. 855-872.e7. [DOI: 10.1016/b978-0-323-24288-2.00089-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
306 Qasrawi SQ, Albarrak AM, Alharbi AS, Nashwan S, Almeneessier AS, Pandi-Perumal SR, Alsaadi MM, BaHammam AS. Narcolepsy in Saudi patients before and after the 2009 H1N1 vaccination. The experience of 2 referral centers. Saudi Med J 2017;38:1196-200. [PMID: 29209667 DOI: 10.15537/smj.2017.12.21046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
307 Lecendreux M, Libri V, Jaussent I, Mottez E, Lopez R, Lavault S, Regnault A, Arnulf I, Dauvilliers Y. Impact of cytokine in type 1 narcolepsy: Role of pandemic H1N1 vaccination ? J Autoimmun 2015;60:20-31. [PMID: 25892508 DOI: 10.1016/j.jaut.2015.03.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
308 Kornum BR. Narcolepsy Type I as an autoimmune disorder. Handb Clin Neurol 2021;181:161-72. [PMID: 34238455 DOI: 10.1016/B978-0-12-820683-6.00012-9] [Reference Citation Analysis]
309 Vuorela A, Freitag TL, Leskinen K, Pessa H, Härkönen T, Stracenski I, Kirjavainen T, Olsen P, Saarenpää-Heikkilä O, Ilonen J, Knip M, Vaheri A, Partinen M, Saavalainen P, Meri S, Vaarala O. Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1. Nat Commun 2021;12:2283. [PMID: 33863907 DOI: 10.1038/s41467-021-22637-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
310 van der Laan JW, Gould S, Tanir JY; ILSI HESI Vaccines and Adjuvants Safety Project Committee. Safety of vaccine adjuvants: focus on autoimmunity. Vaccine 2015;33:1507-14. [PMID: 25659277 DOI: 10.1016/j.vaccine.2015.01.073] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
311 Lafond KE, Englund JA, Tam JS, Bresee JS. Overview of Influenza Vaccines in Children. J Pediatric Infect Dis Soc 2013;2:368-78. [PMID: 26619499 DOI: 10.1093/jpids/pit053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
312 Gu Y, Shimada T, Yasui Y, Tada Y, Kaku M, Okabe N. National surveillance of influenza-associated encephalopathy in Japan over six years, before and during the 2009-2010 influenza pandemic. PLoS One 2013;8:e54786. [PMID: 23355899 DOI: 10.1371/journal.pone.0054786] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
313 Geller G, Dvoskin R, Thio CL, Duggal P, Lewis MH, Bailey TC, Sutherland A, Salmon DA, Kahn JP. Genomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practice. Genome Med 2014;6:106. [PMID: 25593592 DOI: 10.1186/s13073-014-0106-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
314 Hu Z, Jiao X, Liu X. Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design. Front Microbiol 2017;8:1898. [PMID: 29018438 DOI: 10.3389/fmicb.2017.01898] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
315 Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med 2014;275:172-90. [DOI: 10.1111/joim.12150] [Cited by in Crossref: 97] [Cited by in F6Publishing: 80] [Article Influence: 10.8] [Reference Citation Analysis]
316 Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, Svanström H, Mølgaard-Nielsen D, Heijbel H, Dahlström LA, Hallgren J, Sparen P, Jennum P, Mosseveld M, Schuemie M, van der Maas N, Partinen M, Romio S, Trotta F, Santuccio C, Menna A, Plazzi G, Moghadam KK, Ferro S, Lammers GJ, Overeem S, Johansen K, Kramarz P, Bonhoeffer J, Sturkenboom MC. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013;31:1246-54. [PMID: 23246544 DOI: 10.1016/j.vaccine.2012.12.015] [Cited by in Crossref: 159] [Cited by in F6Publishing: 140] [Article Influence: 15.9] [Reference Citation Analysis]